The Trump administration finalized a sweeping PBM transparency rule on Thursday, October 29, 2026, forcing the powerful middlemen of the American prescription drug market to open their books to the employers who pay the bills. The PBM transparency rule, issued by the Labor Department's Employee Benefits Security Administration, requires pharmacy benefit managers to disclose detailed information about how they are paid, including rebates from drug manufacturers, spread pricing and money clawed back from pharmacies, in a move officials say is designed to bring down health care costs for workers and their families.
The Labor Department announced the final rule at a health care pricing transparency event on Thursday morning, with remarks from Labor Secretary Keith Sonderling, Centers for Medicare and Medicaid Services Administrator Mehmet Oz, White House Domestic Policy Council Director Vince Haley and Employee Benefits Security Administration Assistant Secretary Daniel Aronowitz. The event, which began at 10:30 a.m. Eastern time, followed a similar Health and Human Services event earlier in October unveiling a separate health pricing transparency final rule.
Under the new regulation, PBMs must disclose to health plans a wide range of financial information, including payments from drug manufacturers, spread compensation, payments recouped from pharmacies in connection with prescription drugs dispensed to the plan — known in the industry as clawbacks — and price protection arrangements. The rule also requires PBMs to disclose conflicts of interest, clarify their fiduciary role and explain their authority to change a plan's drug formulary, the list of medicines a plan covers and how much patients pay for them.
Reporting by the Wall Street Journal, summarized by Becker's Payer Issues and STAT, said PBMs will have to tell their employer clients upfront about expected compensation and give earnings updates every six months. The regulation is expected to take effect in July 2027 and to apply to self-insured employers, the large companies that pay their workers' medical claims directly rather than buying a fully insured policy. A Labor Department official told the Journal that the rule is intended to help reduce health care costs, aligning with an executive order signed in April 2025.
Pharmacy benefit managers sit at the center of the American drug supply chain, between drug manufacturers, health insurers, employers and pharmacies. When a patient hands over a prescription, it is usually a PBM that decides whether the drug is covered, which pharmacy can dispense it, how much the pharmacy is reimbursed and how much the patient pays at the counter. PBMs also negotiate rebates — large, often confidential discounts — from drug manufacturers in exchange for placing their medicines on a plan's formulary.
That position has made the industry both enormously powerful and deeply controversial. Three companies dominate the market: CVS Health's CVS Caremark, Cigna's Express Scripts and UnitedHealth Group's OptumRx. Industry estimates compiled by Drug Channels put their combined share at about 80 percent of all equivalent prescription claims in 2025, a level of concentration that has barely moved in recent years despite intense political scrutiny. Each of the three is part of a vertically integrated health care giant that also owns insurers, pharmacies or both, a structure critics say creates conflicts of interest at every step.
The practices now targeted by the rule have drawn criticism for years. Spread pricing occurs when an employer or health plan pays a PBM more for a drug than the PBM reimburses the pharmacy, with the PBM keeping the difference. Clawbacks occur when money is recouped from pharmacies after a prescription has already been dispensed. Critics, including community pharmacy groups, argue that both practices inflate costs for employers and squeeze independent pharmacies, while defenders in the industry have argued that rebates and other payments are passed on to clients and help hold down premiums.
The stakes are large. According to the Business Group on Health's 2027 Employer Healthcare Strategy Survey, cited by Becker's, pharmacy spending makes up about one quarter of employer health care spending and was expected to rise 12 percent in 2026. A KFF survey found that just under half of large employers said they receive sufficient insight into rebates and other payments from drug manufacturers to their insurer, administrator or PBM — a transparency gap the new rule is designed to close.
The heart of the rule is a simple principle: the employer paying for a drug benefit should be able to see what its middleman earns from that benefit. PBMs and certain brokers and consultants will have to disclose payments from drug manufacturers, including rebates and any other payments that could steer patients toward particular drugs. Disclosure requirements will also cover group purchasing organizations linked to PBMs, entities that aggregate buying power and have themselves faced scrutiny over their fees.
Beyond the headline payments, the rule reaches into the mechanics that have long frustrated employers. Spread compensation must be disclosed, so a plan can see whether it is paying more than the pharmacy receives. Pharmacy clawbacks must be disclosed, so a plan can see money flowing back after dispensing. Price protection arrangements — deals under which a manufacturer compensates a PBM if a drug's price rises — must also be revealed. Together, the disclosures are meant to let an employer judge whether its PBM is working for the plan or profiting at its expense.
The rule also strengthens the plan's hand in enforcing the new transparency. Health plans will be entitled to an auditor of their choice and to the information needed to meet their legal responsibilities under federal benefits law. That audit right matters because PBM contracts have historically limited employers' ability to verify what they were charged, leaving them dependent on summaries prepared by the very firms they were trying to check.
Bloomberg Law reported that the finalized rule is likely to tee up a legal battle with the industry, which has fought similar measures in the past. When the Labor Department first pitched PBM regulation in January 2026, it was met with PBM opposition, according to the Journal, and related legislation passed in February carried provisions that mainly take effect in 2028. The new rule's July 2027 effective date puts the disclosure regime in place ahead of much of that legislation, giving employers an earlier window into PBM finances.
Community pharmacists welcomed the announcement. The National Community Pharmacists Association, which represents independent pharmacies, said the focus on spread pricing and clawbacks would give health plans new insight into how their money is spent and help keep PBMs accountable to patients and pharmacies. In its announcement of Thursday's event, the association described spread pricing and clawbacks as long-standing features of PBM business practices that have harmed pharmacies and the patients they serve.
The administration framed the rule as part of its broader push to lower drug costs, a theme that has run through its health policy agenda, including the earlier HHS pricing transparency rule and the TrumpRx platform for direct drug purchasing. A Labor Department official told the Wall Street Journal that the rule intends to help reduce health care costs, in line with the April 2025 executive order directing agencies to increase transparency in the drug market.
The PBM industry, which has argued that its negotiations save employers money and that disclosure mandates risk revealing competitively sensitive pricing, has not welcomed past proposals. Some large PBMs, including Cigna's Express Scripts and CVS Caremark, have in recent months rolled out their own price transparency initiatives, a step analysts read as an effort to show good faith while resisting binding federal mandates. The Federal Trade Commission has separately been pursuing settlements with major PBMs over allegations that they inflated insulin list prices, a reminder that the transparency rule arrives alongside active enforcement.
For most Americans, the rule will not change the price printed on a prescription bottle overnight. What it changes is who can see the money moving behind that price. Employers that buy coverage for millions of workers have long complained that they sign drug contracts without knowing what their PBM earns from manufacturers, pharmacies or both. Without that information, they cannot tell whether a rebate touted as a saving is actually a saving, or whether a cheaper drug was kept off the formulary because a rival manufacturer paid more.
The timing amplifies the effect. With pharmacy spending rising sharply, employers are passing more costs to workers through higher premiums, deductibles and copays. A rule that forces disclosure in mid-2027, ahead of the 2028 effective dates in recent legislation, gives benefits consultants and employers a full contracting cycle to renegotiate terms, switch PBMs or demand that rebates be passed through in full. It also gives regulators and researchers a clearer picture of an industry whose finances have been among the least transparent in American health care.
For independent pharmacies, the stakes are existential. Community pharmacies have closed at elevated rates in recent years, particularly in rural counties and low-income neighborhoods, contributing to what researchers call pharmacy deserts. Pharmacists argue that spread pricing and clawbacks have squeezed their margins to unsustainable levels, and they see Thursday's rule as validation of complaints they have made for a decade. If disclosure leads employers to demand fairer reimbursement, some of those pharmacies could survive; if it changes little, the closures are likely to continue.
The immediate question is litigation. Industry groups have challenged PBM regulations before, and Bloomberg Law's assessment that the rule tees up a legal battle suggests a court fight over the Labor Department's authority is likely before the July 2027 effective date. Employers, meanwhile, will begin asking their PBMs how they plan to comply, and benefits consultants are expected to build the new disclosures into contract negotiations for the 2027 and 2028 plan years.
Regulators will also be watching how the rule interacts with the February 2026 legislation and the October CMS proposal on Medicare Part D PBM compensation, which would restrict those payments to flat service fees detached from drug prices. Together, the measures point toward a drug market in which PBM pay is increasingly separated from the price of the drugs themselves — a structural change that, if it holds, would reshape one of the most profitable corners of American health care.
For patients, the practical test will come at the pharmacy counter. If transparency drives employers to choose PBMs that pass rebates through and reimburse pharmacies fairly, out-of-pocket costs could ease and more local pharmacies could stay open. If the disclosures are fought in court or buried in technical filings, the rule's promise will remain unfulfilled. Either way, Thursday's finalization marks the most concrete federal step yet to force the drug market's middlemen to show their working.
A pharmacy benefit manager, or PBM, is a middleman that manages prescription drug benefits for health plans and employers. It negotiates prices and rebates with drug manufacturers, decides which drugs a plan covers, and sets how much pharmacies are paid and patients pay.
It requires PBMs to disclose detailed compensation to employer health plans, including payments from drug manufacturers, spread pricing, pharmacy clawbacks and price protection arrangements, plus conflicts of interest and their authority to change a plan's formulary.
According to Wall Street Journal reporting on the rule, it takes effect in July 2027 and applies to self-insured employers, with PBMs required to disclose expected compensation upfront and provide updates every six months.
CVS Caremark, Express Scripts and OptumRx dominate the market, processing roughly 80 percent of all U.S. prescription claims, according to Drug Channels estimates for 2025.
Not directly or immediately. The rule gives employers visibility into PBM earnings so they can negotiate better contracts, which could lower costs over time — but its effect will depend on litigation, enforcement and how employers use the new information.
Read more: September PCE Inflation Rises to 3.6% as Energy Costs Push Prices Higher, FTC Personalized Pricing Probe: Walmart, Delta, Uber Ordered to Disclose Data Use and US GDP Q3 2026: Economy Grows 3.4% as Investment and Spending Beat Forecasts.
Leave a Comment
| Today's Date:
